Cellid, Co., Ltd.
Financials
Valuation Metrics
Cellid, Co., Ltd.'s Market Cap is ₩504B. At end of 2025 it was ₩844B. Ranked #1740 of 2,436 in KR market (top 71%), #1051 of 1,649 on KOSDAQ (top 64%), #190 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 81%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 50.36B KRW | KR#1,740/2,436 Sec#190/234 |
| Revenue | 10.48B KRW | KR#2,281/2,436 Sec#175/234 |
| Net Income | -10.87B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 114.94B KRW | KR#1,647/2,436 Sec#135/234 |
| Net Assets | 72.69B KRW | KR#1,623/2,436 Sec#137/234 |
| Employees | 56 | KR#1,982/2,436 Sec#176/234 |
| Value | ||
| P/B | 0.69x | KR#1,134/2,436 Sec#61/234 |
| P/S | 4.80x | KR#2,132/2,436 Sec#139/234 |
| FCF Yield | -45.73% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -14.95% | KR#1,990/2,436 Sec#158/234 |
| ROA | -9.46% | KR#2,060/2,436 Sec#156/234 |
| Op. Margin | -97.82% | KR#2,308/2,436 Sec#174/234 |
| Revenue Growth | 104.39% | KR#139/2,436 Sec#20/234 |
| Financial Health | ||
| Debt Ratio | 58.12% | KR#198/2,436 Sec#26/234 |
| Total Debt | 29.38B KRW | KR#1,199/2,436 Sec#96/234 |
| FCF | -23.03B KRW | KR#1,933/2,436 Sec#185/234 |
| Cash | 10.53B KRW | KR#1,645/2,436 Sec#129/234 |
| Current Ratio | 0.66x | KR#2,158/2,436 Sec#205/234 |
| Performance | ||
| 1Y Return | -60.67% | KR#2,243/2,436 Sec#213/234 |
| 1M Return | 18.30% | KR#141/2,436 Sec#8/234 |
| From 52W High | -64.14% | KR#1,913/2,436 Sec#161/234 |
| 1Y MDD | -76.38% | KR#2,198/2,436 Sec#201/234 |
| Trading | ||
| Volume | 686,558 shares | KR#196/2,436 Sec#14/234 |
| Foreign Own. | 1.94% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -394 KRW | KR—/2,436 Sec—/234 |
| BPS | 2,464 KRW | KR#1,918/2,436 Sec#155/234 |
Company Info
Cellid, a bio-venture established in 2006, expanded its business in 2024 by merging with ForBaker Co., Ltd. to establish an e-commerce division. The company develops CeliVax-based anti-cancer immunotherapy vaccines and adenovirus vector-based COVID-19 prophylactic vaccines, while also operating biopharmaceutical contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) services from its 2020 GMP facility. Its anti-cancer immunotherapy vaccines are undergoing clinical and non-clinical trials, and its Omicron-specific COVID-19 vaccine has completed Phase 3 administration. Cellid is headquartered in Gwanak-gu, Seoul.